Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug (:43), the impact of a government shutdown on the agency (10:00), and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations (22:58). More On These Topics From The Pink Sheet BrainStorm’s NurOwn Gets Many, Many Thumbs Down From US FDA Panel: https://pink.citeline.com/PS148915/BrainStorms-NurOwn-Gets-Many-Many-Thumbs-Down-From-US-FDA-Panel Preparing For A Shutdown: US FDA To Retain 81% Of Workforce, Thanks Mostly To User Fees: https://pink.citeline.com/PS148923/Preparing-For-A-Shutdown-US-FDA-To-Retain-81-Of-Workforce-Thanks-Mostly-To-User-Fees Republican Lawmaker Takes Unusual Step Of Attacking FDA Salaries Over Abortion Pill Decisions: https://pink.citeline.com/PS148917/Republican-Lawmaker-Takes-Unusual-Step-Of-Attacking-FDA-Salaries-Over-Abortion-Pill-Decisions Imbruvica, Enbrel, Stelara Offer Best Chance Of Savings From Medicare Negotiation In First Round: https://pink.citeline.com/PS148916/Imbruvica-Enbrel-Stelara-Offer-Best-Chance-Of-Savings-From-Medicare-Negotiation-In-First-Round

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related